Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-loaded DC Vaccine Combined with PD-1 Inhibitor and Radiotherapy for Advanced NSCLC
NCT06752057Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of Neoantigen-loaded DC vaccine in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Objective Response Rate at 32 weeks, Disease Control Rate at 32 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
Neoantigen-loaded DC vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06752057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752057.